Overview

Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is: - To explore the potential role of tacrolimus in the treatment of membranous nephropathy. - To investigate the safety and tolerability of tacrolimus vs methylprednisolone plus cyclophosphamide.
Phase:
N/A
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Nanjing University School of Medicine
Treatments:
Tacrolimus
Criteria
Inclusion Criteria:

- Biopsy-proven idiopathic membranous nephropathy

- Nephrotic syndrome with proteinuria ( > 4 g/day) and serum albumin < 30 g/dl

- Age 18-60 years with informed consent

Exclusion Criteria:

- Patient with abnormal liver function tests

- Prior therapy with sirolimus, CSA, MMF, or azathioprin, cytoxan, chlorambucil,
levamisole, methotrexate, or nitrogen mustard in the last 90 days

- Active/serious infection

- Patient with hepatitis B surface antigen or who is hepatitis C antibody positive

- Patient who is diabetic

- Patient is allergic or intolerant to macrolide antibiotics or tacrolimus